LAGRAN program for area and moments in pharmacokinetic analysis.
about
In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts.Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice.Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumorsPhase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatientsDose-dependent pharmacokinetics of mezlocillin in rats.Ceftriaxone disposition in open-heart surgery patients.Pharmacokinetics of 2',3'-dideoxyinosine in monkeysPharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys.Pharmacokinetics of meropenem in patients with intra-abdominal infections.Pharmacokinetics of antiviral polyoxometalates in rats.Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy.Quantitative relationships between zidovudine exposure and efficacy and toxicityEvaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model.Tolerance and pharmacokinetic interactions of rifabutin and azithromycin.A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors.In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization.Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics.Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjectsBioelectrical impedance modelling of gentamicin pharmacokinetic parametersPharmacokinetics of (-)-2'-3'-dideoxy-3'-thiacytidine in woodchucksContinuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infectionsComparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots.Pharmacokinetics of a water-soluble fullerene in rats.Pharmacokinetics of (-)-beta-D-2-aminopurine dioxolane and (-)-beta-D-2-amino-6-chloropurine dioxolane and their antiviral metabolite (-)-beta-D-dioxolane guanine in rhesus monkeys.Prenatal and postpartum pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) and didanosine (dideoxyinosine) in pigtailed macaques (Macaca nemestrina)Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.Pharmacokinetics of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)uracil in woodchucksPharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infectionVancomycin pharmacokinetics in burn patients and intravenous drug abusersPharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rhesus monkeys.Safety and pharmacokinetics of rimantadine small-particle aerosol.Pharmacokinetics of two multiple-dose mezlocillin regimensPhase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancerPharmacokinetics of amikacin in serum and in tissue contiguous with pressure sores in humans with spinal cord injuryPharmacokinetics of aztreonam in patients with gram-negative infections.Pharmacokinetics and pharmacodynamics of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS and severe AIDS-related complex.
P2860
Q30414963-0E5EEEE9-18F2-4B81-A3BD-AA931272FCDFQ33338530-CE9C3E52-F860-4E47-93B6-5F6C033F9DBDQ33388351-C1A173DA-0E5A-4CCC-B2AB-2751B00B5977Q33391851-C85AB852-621B-41BC-8AE9-44A3FAB81EA1Q33691292-57B75A53-C09C-4B46-8C62-5E2F1F739A38Q33692547-1C02FEBD-D2A9-4601-9E98-2DBA0D564F1FQ33742036-8CE2BF3D-66CB-4E81-BC99-CA8E70DEF81AQ33742082-BCF9A238-9E8E-43C2-824B-4029C1C078F6Q33744728-66C9958F-64D2-46D0-AD87-2DE962CDD055Q33745246-E66FA2A9-5900-442E-9D61-05361BE1A4C6Q33747920-CBD74B75-E009-4424-952C-16C42259207AQ33750885-F679CB48-FE66-4B0D-A1B6-0CF323D00D89Q33751841-D74594D4-1DE8-4718-9F5D-9CE4AB182150Q33756402-56022B88-05EF-450A-B54B-06C588108E9AQ33975896-CE4F79F0-A5A3-4638-8931-ED946AD773AAQ33982133-4A3B6FEF-86F1-4FDF-81E6-0DD16B2CAB28Q34099365-C9619FE7-FE88-4ADB-8803-788929CE360FQ34359903-8C563C1B-8B69-452F-B518-F7E70B57984AQ34392654-059B400A-4A1B-4E88-BCAD-9CBBC31B9CD9Q34392723-52AB3206-0C98-4AC4-8D41-DEDBA73C2DFBQ34397940-ECF39870-1148-4694-A8E7-57717F49333EQ35123010-CB32E060-2D02-45E9-8154-4220587EC71BQ35123123-FDC3E383-AC5F-4F50-AA98-654344C0B572Q35123139-29E132A5-24E2-4C2E-B64C-F3CC7442AF73Q35123155-AAD0B1CB-67C1-4E94-975F-B109D83E6328Q35127705-DFA7D102-17DD-47E4-A84F-F0B793B67559Q35128085-95149D57-792F-4B65-9EF4-44085702A95DQ35128529-940E8527-6AC1-4DC5-A4FD-15F83E3C2995Q35136776-79CBEEF6-4FE9-4006-9A37-D1C1EC5684E5Q35138496-69083680-3DBA-41CD-B037-BD3DF1038DF5Q35138989-1611B731-8218-4785-8367-43BFF4197A74Q35249948-D535D6D5-4E2A-4AB2-B524-EDD39B19417DQ35253581-747C8D96-605A-48D0-AD9A-0DCB0F4AEE16Q35262604-EC3FB0D6-DEBA-4D62-9C6A-AF952A557028Q35282312-CFFF94FC-EC06-4222-A1D9-B7344F024BCBQ35306618-C3698701-982D-4A14-8637-F3A08C933BFCQ35469572-82E7E027-673D-4B05-AA8E-29FB5876F0D5Q35565358-1069FE08-319E-433E-940F-2107D2894C15Q35568767-FFAC7885-79DB-4EEA-9B43-60E0744E8C1CQ35810392-2F217A12-F09D-401D-BBB9-3649B763D4C1
P2860
LAGRAN program for area and moments in pharmacokinetic analysis.
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年学术文章
@wuu
1983年学术文章
@zh
1983年学术文章
@zh-cn
1983年学术文章
@zh-hans
1983年学术文章
@zh-my
1983年学术文章
@zh-sg
1983年學術文章
@yue
1983年學術文章
@zh-hant
name
LAGRAN program for area and moments in pharmacokinetic analysis.
@en
LAGRAN program for area and moments in pharmacokinetic analysis.
@nl
type
label
LAGRAN program for area and moments in pharmacokinetic analysis.
@en
LAGRAN program for area and moments in pharmacokinetic analysis.
@nl
prefLabel
LAGRAN program for area and moments in pharmacokinetic analysis.
@en
LAGRAN program for area and moments in pharmacokinetic analysis.
@nl
P1476
LAGRAN program for area and moments in pharmacokinetic analysis.
@en
P2093
P304
P356
10.1016/0010-468X(83)90082-X
P577
1983-06-01T00:00:00Z